Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Centocor’s Centoxin

Executive Summary

U.S. Army seeking approval from FDA to use the monoclonal antibody product for treatment of septic shock in U.S. troops stationed in the Middle East for "Operation Desert Shield." The military has signed an open-ended contract with Centocor to purchase 200 doses of Centoxin, and possibly additional doses, at $2,500 per dose. The company is providing the Army with the information it needs to obtain a special approval (a "combative IND"?) since the drug's approval for marketing in the U.S. is currently pending.
UsernamePublicRestriction

Register

PS018099

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel